Autifony Therapeutics initiates QuicK+fire, a pilot study of AUT00063 in adult cochlear implant users

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss, today announced the start of a pilot study (called QuicK+fire) to evaluate its lead compound, AUT00063, in adult cochlear implant (CI) users. The study, which will be conducted in the UK, is aimed at helping to improve the hearing of adult CI users, particularly in challenging environments such as with background noise. AUT0063 is currently being tested in a Phase IIa clinical trial in age related hearing loss in the United States. 

Read More